JP2023542900A5 - - Google Patents
Info
- Publication number
- JP2023542900A5 JP2023542900A5 JP2023517935A JP2023517935A JP2023542900A5 JP 2023542900 A5 JP2023542900 A5 JP 2023542900A5 JP 2023517935 A JP2023517935 A JP 2023517935A JP 2023517935 A JP2023517935 A JP 2023517935A JP 2023542900 A5 JP2023542900 A5 JP 2023542900A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010981835.5 | 2020-09-17 | ||
| CN202010981835 | 2020-09-17 | ||
| CN202011025265.9A CN114195894B (zh) | 2020-09-17 | 2020-09-25 | 一种靶向4-1bb的抗体及其应用 |
| CN202011025265.9 | 2020-09-25 | ||
| PCT/CN2021/118955 WO2022057875A1 (zh) | 2020-09-17 | 2021-09-17 | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542900A JP2023542900A (ja) | 2023-10-12 |
| JP2023542900A5 true JP2023542900A5 (https=) | 2024-09-18 |
| JPWO2022057875A5 JPWO2022057875A5 (https=) | 2024-09-18 |
Family
ID=80645420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517935A Pending JP2023542900A (ja) | 2020-09-17 | 2021-09-17 | ４－１ｂｂを標的とする単一ドメイン抗体、その融合タンパク質、その医薬組成物及び使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230357422A1 (https=) |
| EP (1) | EP4215547A4 (https=) |
| JP (1) | JP2023542900A (https=) |
| KR (1) | KR20230070238A (https=) |
| CN (2) | CN114195894B (https=) |
| AU (1) | AU2021342525A1 (https=) |
| CA (1) | CA3195676A1 (https=) |
| WO (1) | WO2022057875A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250075621A (ko) * | 2022-09-20 | 2025-05-28 | 바이오세우스 인크. | 항체 및 종양 저항에서의 이의 용도 |
| KR20250157389A (ko) * | 2023-03-01 | 2025-11-04 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Fap/4-1bb/cd40 결합 분자 및 이의 의학적 용도 |
| WO2025002405A1 (zh) * | 2023-06-30 | 2025-01-02 | 百奥泰生物制药股份有限公司 | 4-1bb结合蛋白 |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2025214249A1 (en) * | 2024-04-12 | 2025-10-16 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| PT2614082T (pt) * | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| WO2019092452A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| CN109970865B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd137双向激活共刺激分子受体及其用途 |
| CA3089260A1 (en) * | 2018-01-22 | 2019-07-25 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN110627906B (zh) * | 2019-10-10 | 2020-07-28 | 上海洛启生物医药技术有限公司 | 抗pd-l1/4-1bb双特异性抗体及其用途 |
-
2020
- 2020-09-25 CN CN202011025265.9A patent/CN114195894B/zh active Active
-
2021
- 2021-09-17 JP JP2023517935A patent/JP2023542900A/ja active Pending
- 2021-09-17 EP EP21868697.0A patent/EP4215547A4/en active Pending
- 2021-09-17 KR KR1020237012083A patent/KR20230070238A/ko active Pending
- 2021-09-17 AU AU2021342525A patent/AU2021342525A1/en active Pending
- 2021-09-17 CA CA3195676A patent/CA3195676A1/en active Pending
- 2021-09-17 US US18/245,691 patent/US20230357422A1/en active Pending
- 2021-09-17 CN CN202180062285.XA patent/CN116490206A/zh active Pending
- 2021-09-17 WO PCT/CN2021/118955 patent/WO2022057875A1/zh not_active Ceased